Indication expansion (also known as drug repositioning, drug repurposing) represents an opportunity to leverage compounds that already have a well-studied safety profiles for new patient cohorts. One main strategy for identifying novel indications for a compound is using a target based approach that combines knowledge on a drugs mechanism of action in tandem with biomarker based knowledge of an indication. This session will walk through this approach within MetaCore using Vandetanib, an approved oncology drug as a starting point of the indication expansion workflow. Specific questions to address using MetaCore’s various functionalities will include:
1.) What experimental evidence is there for Vandetanib inhibition activity?
2.) What diseases have biomarkers with increased mRNA levels of the tyrosine-protein kinase Mer?
3.) What pathways could be effected when Vandetanib engages Mer? How do these pathways overlap with COPD biomarkers? How do these biomarkers connect to each other in a network context?